CML-261 |
PEXIDARTINIB |
PLX-3397 |
PLX3397 |
Drug Class | Kinase Inhibitors |
Pharmaceutical Developer | Plexxicon |
Source Reported Drug Name(s) | PLX3397 |
Drug Class | Kinase Inhibitor |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
Drug Categories | amines |
Drug Categories | antineoplastic agents |
Drug Categories | cytochrome p-450 cyp2b6 inducers |
Drug Categories | cytochrome p-450 cyp2b6 inducers (strength unknown) |
Drug Categories | cytochrome p-450 cyp2b6 inhibitors |
Drug Categories | cytochrome p-450 cyp2b6 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors |
Drug Categories | cytochrome p-450 cyp2c9 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a inducers |
Drug Categories | cytochrome p-450 cyp3a inhibitors |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inducers |
Drug Categories | cytochrome p-450 cyp3a4 inducers (weak) |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (weak) |
Drug Categories | cytochrome p-450 cyp3a4 substrates |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inducers |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | hepatotoxic agents |
Drug Categories | mate 1 inhibitors |
Drug Categories | mate 2 inhibitors |
Drug Categories | mate inhibitors |
Drug Categories | narrow therapeutic index drugs |
Drug Categories | oatp1b1/slco1b1 inhibitors |
Drug Categories | oatp1b3 inhibitors |
Drug Categories | pyridines |
Drug Categories | tyrosine kinase inhibitors |
Drug Categories | ugt1a1 inhibitors |
Drug Categories | ugt1a4 substrates |
inhibitor (inhibitory) |
Mechanism of Interaction | Macrophage colony stimulating factor receptor inhibitor |
Direct Interaction | yes |
Approval Status | Phase I |
inhibitor (inhibitory) |
Indication/Tumor Type | gastrointestinal stromal tumor |
Response Type | sensitive |
Approval Status | Preclinical - Cell line xenograft |
inhibitor (inhibitory) |
Reported Cancer Type | Prostate |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
n/a |
Drug family | Pan-TK inhibitor |
Alteration | NF1:del |
Alteration | NF1:. |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
PEXIDARTINIB | DrugBank Drug Name |
1029044-16-3 | CAS Number |
Turalio | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
PLX3397 | Development Name |
PLX108-01 | Development Name |
Drug Class | Kinase Inhibitors |
PLX3397 | Drug Trade Name |
PLX3397 | Drug Development Name |
Drug Class | Kinase Inhibitor |
Source Reported Drug Name(s) | PLX3397 |
Pharmaceutical Developer | Plexxicon |
D09TAB | TTD Drug ID |
PEXIDARTINIB | GuideToPharmacology Ligand Name |